Stay updated with breaking news from Oladapoo Yeku. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The investigational CAR T-cell therapy GD2-CART01 showed preliminary antitumor activity and safety in pediatric patients with relapsed or refractory high-risk neuroblastoma, according to data from a phase 1/2 trial.
A novel chimeric antigen receptor T-cell therapy induced clinically impactful antitumor responses in 63% of younger patients with relapsed or refractory, high-risk neuroblastoma, results of a phase 1/phase 2 trial showed.The findings, published in The New England Journal of Medicine, suggest the investigational agent also has a manageable safety profile similar to other CAR T-cell therapies,
Children with relapsed or treatment-refractory neuroblastoma could soon be treated with third-generation of CAR T cells with a 'suicide' safety switch, after a promising results from phase 1/2 trial.